Thiazolidinedione-induced lipid droplet formation during osteogenic differentiation

Journal of Endocrinology

Volumn 223, Issue 2, 2014, Pages 119-132

  van de Vyver, M ^a   Andrag, E ^a   Cockburn, I L ^a   Ferris, W F ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Mesenchymal stem cells; Netoglitazone; Pioglitazone; Rosiglitazone

Indexed keywords

COLLAGEN TYPE 1; COMPLEMENT FACTOR D; FAT DROPLET; GLITAZONE DERIVATIVE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR MSX2; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADIPOGENESIS; ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; LIPID STORAGE; MALE; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST; RAT; SUBCUTANEOUS FAT; WHITE ADIPOSE TISSUE; ADIPOCYTE; ANIMAL; CELL CULTURE; DRUG EFFECTS; LIPID METABOLISM; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; LIPID DROPLETS; LIPID METABOLISM; MALE; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84915756216     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0425     Document Type: Article

References (51)

1. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U-I, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K et al. 2004 PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. Journal of Clinical Investigation 113 846-855. (doi:10.1172/JCI200419900)
2. An SJ, Boyd R, Wang Y, Qiu X & Wang HD 2006 Endothelin-1 expression in vascular adventitial fibroblasts. American Journal of Physiology. Heart and Circulatory Physiology 290 H700-H708. (doi:10.1152/ ajpheart.00326.2005)
3. Beck GR Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D et al. 2013 The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Translational Research 161 145-155. (doi:10.1016/j.trsl.2012.08.006)
4. Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE et al. 2006 Peroxisome proliferator-activated receptor (PPAR)-α agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: a comparison with PPARg agonism. Endocrinology 147 4252-4262. (doi:10.1210/en.2005-1535)
5. Bruedigam C, Eijken M, Koedam M, van de Peppel J, Drabek K, Chiba H & van Leeuwen JP 2010 A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells 28 916-927. (doi:10.1002/stem.405)
6. Cariou B, Charbonnel B & Staels B 2012 Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends in Endocrinology and Metabolism 23 205-215. (doi:10.1016/j.tem.2012.03.001)
7. Chang F, Jaber LA, Berlie HD & O'Connell MB 2007 Evolution of peroxisome proliferator-activated receptor agonists. Annals of Pharmacotherapy 41 973-983. (doi:10.1345/aph.1K013)
8. Cho E-S, Kim M-K, Son Y-O, Lee K-S, Park S-M & Lee J-C 2012 The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Molecules and Cells 33 173-181. (doi:10.1007/ s10059-012-2240-z)
9. Duan Z, ZhaoX, Fu X, Su C, Xin L, Saarikettu J, YangX, Yao Z, Silvennoinen O, WeiMet al. 2014Tudor-SN, anovel coactivator ofperoxisomeproliferatoractivated receptor γ protein, is essential for adipogenesis. Journal of Biological Chemistry 289 8364-8374. (doi:10.1074/jbc.M113.523456)
10. Ducy P, Zhang R, Geoffroy V, Ridall AL & Karsenty G 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89 747-754. (doi:10.1016/S0092-8674(00)80257-3)
11. Dusserre E, Moulin P & Vidal H 2000 Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochimica et Biophysica Acta 1500 88-96. (doi:10.1016/S0925-4439(99)00091-5)
12. Fukuen S, Iwaki M, Yasui A, MakishimaM, Matsuda M, Shimomura I 2005 Sulfonylurea agents exhibit peroxisome proliferator-activated receptor γ agonistic activity. Journal of Biological Chemistry 280 23653-23659. (doi:10.1074/jbc.M412113200)
13. Gitt AK, Bramlage P, Binz C, Krekler M, Deeg E & Tschöpe D 2012 Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany. Results of the DiaRegis registry. Herz 37 294-300. (doi:10.1007/s00059-012-3611-3)
14. Huang JI, Beanes SR, Zhu M, Lorenz HP, Hedrick MH & Benhaim P 2002 Rat extramedullary adipose tissue as a source of osteochondrogenic progenitor cells. Plastic and Reconstructive Surgery 109 1033-1043.
15. Johnson TE, Vogel R, Rutledge SJ, Rodan G & Schmidt A 1999 Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 140 3245-3254. (doi:10.1210/endo.140.7.6797)
16. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G & Rosiglitazone Fluid Retention Study Group 2006 Effect of various diuretic treatments on rosiglitazone-induced fluid retention. Journal of the American Society of Nephrology 17 3482-3490. (doi:10.1681/ASN.2006060606)
17. Kato S, Kawabata N, Suzuki N, Ohmura M & Takagi M 2009 Bone morphogenetic protein-2 induces the differentiation of a mesenchymal progenitor cell line, ROB-C26, into mature osteoblasts and adipocytes. Life Sciences 84 302-310. (doi:10.1016/j.lfs.2008.12.011)
18. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M et al. 1997 Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89 755-764. (doi:10.1016/S0092-8674(00)80258-5)
19. Kuroda S, Virdi AS, Dai Y, Shott S & Sumner DR 2005 Patterns and localization of gene expression during intramembranous bone regeneration in the rat femoral marrow ablation model. Calcified Tissue International 77 212-225. (doi:10.1007/s00223-004-0267-x)
20. Lafontan M & Berlan M 2003 Do regional differences in adipocyte biology provide new pathophysiological insights? Trends in Pharmacological Sciences 24 276-283. (doi:10.1016/S0165-6147(03)00132-9)
21. Lazarenko OP, Rzonca SO, Suva LJ & Lecka-Czernik B 2006 Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat. Bone 38 74-84. (doi:10.1016/j.bone.2005.07.008)
22. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC & Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. Journal of Cellular Biochemistry 74 357-371. (doi:10.1002/(SICI)1097-4644 (19990901)74:3<357::AID-JCB5>3.0.CO;2-7)
23. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC & Jilka RL 2002 Divergent effects of selective peroxisome proliferatoractivated receptor-γ2 ligands on adipocyte vs osteoblast differentiation. Endocrinology 143 2376-2384. (doi:10.1210/endo.143.6.8834)
24. Lee J-Y, Kim J-K, Lee S-J, Lee E-J, Shin S-Y, Jin Q, Yoon D-Y, Woo E-R & Kim Y-M 2012 Binding model of amentoflavone to peroxisome proliferator-activated receptor γ. Bulletin of the Korean Chemical Society 33 1475-1479. (doi:10.5012/bkcs.2012.33.5.1475)
25. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM & Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). Journal of Biological Chemistry 270 12953-12956. (doi:10.1074/jbc.270. 22.12953)
26. Liu LS, Tanaka H, Ishii S & Eckel J 1998 The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Endocrinology 139 4531-4539. (doi:10.1210/endo.139.11.6310)
27. Loke YK, Singh S & Furberg CD 2009 Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Canadian Medical Association Journal 180 32-39. (doi:10.1503/cmaj.080486)
28. Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K & Lewis JD 2012 Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. Journal of the National Cancer Institute 104 1411-1421. (doi:10.1093/jnci/djs328)
29. Nakashima K & de Crombrugghe B 2003 Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends in Genetics 19 458-466. (doi:10.1016/S0168-9525(03)00176-8)
30. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR & de Crombrugghe B 2002 The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108 17-29. (doi:10.1016/S0092-8674(01) 00622-5)
31. Nishii N, Arai M, Yanai N, Togari A & Nakabayashi T 2009 Effect of bone morphogenetic protein-2 (BMP-2) or troglitazone, as an inducer of osteogenic cells or adipocytes, on differentiation of a bone marrow mesenchymal progenitor cell line established from temperaturesensitive (ts) simian virus (SV) 40 T-antigen gene transgenic mice. Biological and Pharmaceutical Bulletin 32 10-17. (doi:10.1248/bpb.32.10)
32. Owen M 1988 Marrow stromal stem cells. Journal of Cell Science. Supplement 10 63-76. (doi:10.1242/jcs.1988.Supplement_10.5)
33. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29 e45. (doi:10.1093/ nar/29.9.e45)
34. Pickavance L, Widdowson PS, King P, Ishii S, Tanaka H & Williams G 1998 The development of overt diabetes in young Zucker diabetic fatty (ZDF) rats and the effects of chronic MCC-555 treatment. British Journal of Pharmacology 125 767-770. (doi:10.1038/sj.bjp.0702158)
35. Pickavance LC,Widdowson PS, Foster JR, Williams G & Wilding JPH 2003 Chronic treatment with the thiazolidinedione,MCC-555, is associated withreductions in nitricoxide synthase activityand β-cell apoptosis in the pancreas of the Zucker diabetic fatty rat. International Journal of Experimental Pathology 84 83-89. (doi:10.1046/j.1365-2613.2003.00337.x)
36. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H & Lazar MA 1998 A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. Journal of Biological Chemistry 273 32679-32684. (doi:10.1074/jbc.273.49.32679)
37. Ren D, Collingwood TN, Rebar EJ, Wolffe AP & Camp HS 2002 PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes and Development 16 27-32. (doi:10.1101/gad.953802)
38. Sadie-Van Gijsen H, Crowther NJ, Hough FS & Ferris WF 2010 Depotspecific differences in the insulin response of adipose-derived stromal cells. Molecular and Cellular Endocrinology 328 22-27. (doi:10.1016/j. mce.2010.06.009)
39. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y & Sawada H 2000 Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochemical and Biophysical Research Communications 278 704-711. (doi:10.1006/bbrc.2000.3868)
40. Satokata I,MaL, Ohshima H, BeiM,WooI, Nishizawa K, Maeda T, Takano Y, Uchiyama M, Heaney S et al. 2000 Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nature Genetics 24 391-395. (doi:10.1038/74231)
41. Sewter C, Blows F, Considine R, Vidal-Puig A & O'Rahilly S 2002 Differential effects of adiposity on peroxisomal proliferator-activated receptor γ1 and γ2 messenger ribonucleic acid expression in human adipocytes. Journal of Clinical Endocrinology and Metabolism 87 4203- 4207. (doi:10.1210/jc.2002-011511)
42. Shockley KR, Rosen CJ, Churchill GA & Lecka-Czernik B 2007 PPARg2 regulates a molecular signature of marrow mesenchymal stem cells. PPAR Research 2007 81219. (doi:10.1155/2007/81219)
43. Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R & Stürmer T 2009 A cohort study of thiazolidinediones and fractures in older adults with diabetes. Journal of Clinical Endocrinology and Metabolism 94 2792-2798. (doi:10.1210/jc.2008-2157)
44. Sottile V & Seuwen K 2000 Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone). FEBS Letters 475 201-204. (doi:10.1016/S0014-5793(00)01655-0)
45. Tanabe Y, Koga M, Saito M, Matsunaga Y & Nakayama K 2004 Inhibition of adipocyte differentiation by mechanical stretching through ERKmediated downregulation of PPARγ2. Journal of Cell Science 117 3605-3614. (doi:10.1242/jcs.01207)
46. Upton R, Widdowson PS, Ishii S, Tanaka H & Williams G 1998 Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. British Journal of Pharmacology 125 1708-1714. (doi:10.1038/ sj.bjp.0702245)
47. Van Dieren S,Czernichow S, Chalmers J, Kengne AP, de Galan BE, PoulterN, Woodward M, Beulens JWJ, Grobbee DE, van der Schouw YT et al. 2012 Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes, Obesity and Metabolism 14 464-469. (doi:10.1111/j.1463-1326.2012.01556.x)
48. Van Wijngaarden P, Brereton HM, Coster DJ & Williams KA 2007 Stability of housekeeping gene expression in the rat retina during exposure to cyclic hyperoxia. Molecular Vision 13 1508-1515.
49. Wang L, Li L, Gao H & Li Y 2012 Effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone mesenchymal stem cells into adipocytes. Journal of Huazhong University of Science and Technology. Medical Sciences 32 530-533. (doi:10.1007/s11596-012-0091-x)
50. Yau H, Rivera K, Lomonaco R & Cusi K 2013 The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Current Diabetes Reports 13 329-341. (doi:10.1007/ s11892-013-0378-8)
51. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS & Reddy JK 1995 Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPAR γ) gene: alternative promoter use and different splicing yield two mPPAR γ isoforms. PNAS 92 7921-7925. (doi:10.1073/pnas.92.17.7921)